Compare Medpace Holdings Inc (MEDP) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Norfolk Southern Corporation — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Norfolk Southern Corporation trades at $317.62 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 4.2× Medpace Holdings Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Norfolk Southern Corporation for 33 Days on average.
| MEDP | NSC | |
|---|---|---|
Market Cap | $16.82B | $71.20B |
Volume | 223,093 | 555,248 |
Sector | Health | Industrials |
52-Week High | $630.19 | $352.98 |
52-Week Low | $393.42 | $278.19 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | $16.44B | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Norfolk Southern (NSC) trades at $317.79, up 1.47% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 22, 2026. Fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though revenue growth is modest. The proposed merger with Union Pacific is a key development, gaining regulatory and customer support.
The outlook is positive, supported by earnings momentum and merger potential, offering upside to the $361.86 consensus price target. Risks include merger approval uncertainty, fuel cost pressures noted in September 2026, and a high P/E ratio of 27.05. Institutional interest remains strong, with recent investments from firms like Bank of America.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
